Given the well-established associations of genomic alterations with the prognosis of prostate cancer patients, our objective was to explore the prognostic significance of BAP1 alone and in combination with common PCa genomic alterations such as PTEN, ERG, P53, and AR (Figure 2). This evidence concerns the gene TP53 and prostate carcinoma.